Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246
John W. Huggins(United States Army Medical Research Institute of Infectious Diseases), Arthur J. Goff(United States Department of the Army), Lisa E. Hensley(United States Department of the Army), Eric M. Mucker(United States Department of the Army), Josh Shamblin(United States Department of the Army), Carly Wlazlowski(United States Department of the Army), Wendy Johnson(United States Department of the Army), Jennifer Chapman(United States Department of the Army), Thomas Larsen(United States Department of the Army), Nancy Twenhafel(United States Department of the Army), Kevin L. Karem(Centers for Disease Control and Prevention), Inger K. Damon(Centers for Disease Control and Prevention), Chelsea M. Byrd(Siga Technologies (United States)), Tové C. Bolken(Siga Technologies (United States)), Robert Jordan(Siga Technologies (United States)), Dennis E. Hruby(Siga Technologies (United States))
Cited by 176Open Access
Abstract
ST-246, a potent orthopoxvirus egress inhibitor, is safe and effective at preventing disease and death in studies of small-animal models involving challenge by several different pathogenic poxviruses. In this report, the antiviral efficacy of ST-246 in treatment of nonhuman primates infected with variola virus or monkeypox virus was assessed. The data indicate that oral dosing once per day with ST-246 protects animals from poxvirus disease, as measured by reductions in viral load and numbers of lesions and enhancement of survival.
Related Papers
No related papers found
Powered by citation graph analysis